All In Biotech

Drug Trial Radar · NCT01695356

Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma

A Double Blind Randomized Study Comparing the Ultraviolet (UV) Photoprotection With UV Plus Visible Light Photoprotection in the Treatment of Melasma.

Last checked: Nov 19, 2026Latest source record: Dec 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

68

Actual

Start

Sep 2012

Primary completion

Oct 2013

Study completion Nov 2013

Sponsor

Lead sponsor
Universidad Autonoma de San Luis PotosíAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hospital Central "Dr. Ignacio Morones Prieto"
First posted
Sep 28, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 25 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Melasma is an acquired discoloration of the skin characterized by brown colour changes commonly on the face. The duration of this double-blind clinical trial will be 12 weeks. The control group will receive treatment with topical Hydroquinone (4%) and a Broad spectrum UV sunscreen. The experimental group, 4% topical hydroquinone and a Broad spectrum UV-visible light sunscreen. Visible light has melanotic properties and avoiding it can be part of the treatment for melasma patients. The estimated number of subjects to be recruited and randomized for the study is at least 25 per group. The purpose of this study is determine if there is a difference in the improvement between these two sunscreens types. Melasma Area and Severity Index (MASI) score will be assessed at the beginning of the study and at weeks 4, 8, and 12. Photographs, colorimetry and histological assessment will be also evaluated. Occurrence of adverse effects will also be recorded.

Conditions

  • Melasma

Interventions

  • 290-400 nm sunscreenDrug

    A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.

  • 290-800 nm sunscreenDrug

    A UV-visible light spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Depigmentation of melasma lesions by ColorimetryTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Department. Hospital Central "Dr. Ignacio Morones Prieto"

    San Luis Potosí City, San Luis Potosí, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.